Feed 207940.KS
Summary
57 / 100 · Bulios Score
Valuation 10Growth -Profitability 85Quality 76Debt 98Stability 0
What speaks for it
- Out of every 100 KRW of revenue, 41 KRW is left as net profit.
- It earns 15 KRW a year on every 100 KRW of invested capital.
What to watch
- You pay 35.3 KRW for 1 KRW of yearly profit, a lot for its sector.
- It missed profit estimates 5 times in the last 8 quarters.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveP/E today 35.3
Biotechnology industry median
Today you pay 35.3 KRW for 1 KRW of yearly profit.
Valuation in detailIs it growing?
Revenue (KRW)
201420252026
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Very wellWhere 100 KRW of revenue goes
- Cost of sales 18 KRW
- Research and development 0.9 KRW
- Sales and administration 38 KRW
- Taxes and other 2.2 KRW
- Net profit 41 KRW
Net profit, industry median (Biotechnology) -7.1 KRW
Out of every 100 KRW of revenue, 41 KRW is left as net profit.
Profitability in detailIs it financially healthy?
YesCash and short-term investments ₩1.62T
Debt ₩1.19T
Free cash flow over 12 months ₩1.46T
It could repay all its debt from a single year of free cash flow. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
No coverageNo analyst covers this stock.
Analysts in detail